Literature DB >> 30389335

Molecular epidemiology of invasive and non-invasive group B Streptococcus circulating in Serbia.

Ina Gajic1, Celine Plainvert2, Dusan Kekic1, Nicolas Dmytruk3, Vera Mijac1, Asmaa Tazi4, Philippe Glaser5, Lazar Ranin1, Claire Poyart2, Natasa Opavski6.   

Abstract

Streptococcus agalactiae (group B Streptococcus, GBS) remains the leading cause of invasive diseases in neonates and an important cause of infections in the elderly. The aim of this study was to access the prevalence of GBS genito-rectal colonisation of pregnant women and to evaluate the genetic characteristics of invasive and non-invasive GBS isolates recovered throughout Serbia. A total of 432 GBS isolates were tested for antimicrobial susceptibility, capsular polysaccharide (CPS) types and the presence of the hvgA gene. One hundred one randomly selected isolates were further characterized by clustered regularly interspaced short palindromic repeats (CRISPRs) analysis and/or multilocus sequence typing (MLST). The prevalence of GBS colonization in pregnant women was 15%. Overall, six capsular types (Ia, Ib, II to V) were identified, the most common being III (32.2%) and V (25.2%). The hiper-virulent clone type III/ST17 was present in 43.1% and 6.3% (p < 0.05) of paediatric and adults isolates, respectively. Comparative sequence analysis of the CRISPR1 spacers content indicated that a few clones comprised the vast majority of the tested GBS isolates. Thus, it was estimated that dominant clones recovered from infants were CPS III/ST17 in late-onset infections (19/23; 82.6%), and Ia/ST23 in early-onset disease (44.4%). Conversely, genotype CPS V/ST1 was the most prevalent in adults (4/9; 25.4%). All isolates were susceptible to penicillin. Macrolide resistance (23.1%) was strongly associated with the ermB gene and constitutive resistance to clindamycin (63.9%). The majority of strains was resistant to tetracycline (86.6%), mostly mediated by the tetM gene (87.7%). GBS isolates of CPS V/ST1 and CPS III/ST23 were significantly associated with macrolide and tetracycline resistance, respectively. In conclusion, hyper-virulent CPS III/ST17 and V/ST1 were recognized as dominant GBS clones in this study.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  CRISPR; Capsular type; Hyper-virulent clone ST17; Neonates; Pregnant women; Streptococcus agalactiae

Mesh:

Substances:

Year:  2018        PMID: 30389335     DOI: 10.1016/j.ijmm.2018.10.005

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  12 in total

1.  Population Genomics Reveals Distinct Temporal Association with the Emergence of ST1 Serotype V Group B Streptococcus and Macrolide Resistance in North America.

Authors:  M Belén Cubria; Luis Alberto Vega; William C Shropshire; Misu A Sanson; Brittany J Shah; Shrijana Regmi; Marcia Rench; Carol J Baker; Anthony R Flores
Journal:  Antimicrob Agents Chemother       Date:  2021-10-11       Impact factor: 5.938

2.  High prevalence of group B streptococcus ST17 hypervirulent clone among non-pregnant patients from a Hungarian venereology clinic.

Authors:  Szilvia Kardos; Adrienn Tóthpál; Krisztina Laub; Katalin Kristóf; Eszter Ostorházi; Ferenc Rozgonyi; Orsolya Dobay
Journal:  BMC Infect Dis       Date:  2019-11-28       Impact factor: 3.090

3.  Increasing Resistance and Changes in Distribution of Serotypes of Streptococcus agalactiae in Poland.

Authors:  Dorota Kaminska; Magdalena Ratajczak; Anna Szumała-Kąkol; Jolanta Dlugaszewska; Dorota M Nowak-Malczewska; Marzena Gajecka
Journal:  Pathogens       Date:  2020-06-29

Review 4.  Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates.

Authors:  Fiorella Bianchi-Jassir; Proma Paul; Ka-Ning To; Clara Carreras-Abad; Anna C Seale; Elita Jauneikaite; Shabir A Madhi; Neal J Russell; Jenny Hall; Lola Madrid; Quique Bassat; Gaurav Kwatra; Kirsty Le Doare; Joy E Lawn
Journal:  Vaccine       Date:  2020-09-02       Impact factor: 3.641

5.  Molecular Characterization of Hospital- and Community-Acquired Streptococcus agalactiae Isolates among Nonpregnant Adults in Isfahan, Iran.

Authors:  Tahereh Motallebirad; Hossein Fazeli; Saba Jalalifar; Darioush Shokri; Sharareh Moghim; Bahram Nasr Esfahani
Journal:  Adv Biomed Res       Date:  2020-09-30

6.  Prevalence, population structure, distribution of serotypes, pilus islands and resistance genes among erythromycin-resistant colonizing and invasive Streptococcus agalactiae isolates recovered from pregnant and non-pregnant women in Isfahan, Iran.

Authors:  Tahereh Motallebirad; Hossein Fazeli; Ataollah Ghahiri; Dariush Shokri; Saba Jalalifar; Sharareh Moghim; Bahram Nasr Esfahani
Journal:  BMC Microbiol       Date:  2021-05-04       Impact factor: 3.605

7.  Trends in molecular characteristics and antimicrobial resistance of group B streptococci: a multicenter study in Serbia, 2015-2020.

Authors:  Dusan Kekic; Ina Gajic; Natasa Opavski; Milan Kojic; Goran Vukotic; Aleksandra Smitran; Lidija Boskovic; Marina Stojkovic; Lazar Ranin
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

8.  Macrolide-resistance, capsular genotyping and associated factors of group B Streptococci colonized pregnant women in Isfahan, Iran.

Authors:  Soodabeh Rostami; Leila Moeineddini; Fereshteh Ghandehari; Marzieh Rahim Khorasani; Parisa Shoaei; Nasim Ebrahimi
Journal:  Iran J Microbiol       Date:  2021-04

9.  CRISPR Typing Increases the Discriminatory Power of Streptococcus agalactiae Typing Methods.

Authors:  Clémence Beauruelle; Ludovic Treluyer; Adeline Pastuszka; Thierry Cochard; Clément Lier; Laurent Mereghetti; Philippe Glaser; Claire Poyart; Philippe Lanotte
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640

10.  Evaluation of the Results of Group B Streptococcus Screening by MALDI-TOF MS among Pregnant Women in a Hungarian Hospital.

Authors:  Marianna Ábrók; Petra Tigyi; Markus Kostrzewa; Katalin Burián; Judit Deák
Journal:  Pathogens       Date:  2019-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.